Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Agilent Technologies’ $246.2 million acquisition of fellow biotech company Stratagene Corp. illustrates that consolidation is big these days in the health sciences, said LATHAM & WATKINS partner Thomas Edwards, whose firm represented Stratagene. As in more established fields, biotech businesses are finding that mergers create economies of scale, he said. “I think there’s consolidation in business generally that’s going on,” Edwards said. “Larger organizations can handle business more efficiently than smaller ones in a lot of areas.” That means that once a smaller company gets its legs under it, it becomes ripe for acquisition. “Larger businesses want companies that are stable and profitable,” the San Diego partner said. “A lot of developmental businesses go through their R&D, periods where they’re losing money and getting on their feet.” Fenwick & West partner Douglas Cogen led the team working on behalf of Santa Clara’s Agilent, and said the deal, negotiated entirely by phone, was straightforward. Also, as with most tech deals, intellectual property played a key role in negotiations, he said. “IP is critical to the value of the transaction � [to] the value of the company, the strategic fit, how the acquirer’s products can be used,” he said. “They’re all vital pieces of why these companies exist.” Cogen said the acquisition will help Agilent strengthen its biological diagnostics business. Joining his team from Fenwick were partners Lynda Twomey and Sergio Garcia of the San Francisco office, and Scott Spector, Blake Martell and Mark Ostrau from the Mountain View office. Also working from Mountain View were associates Rochelle Levy Karr, Spencer Glende and Christa Gaines. Cogen also said Agilent attorneys Marie Huber, Monifa Clayton, Richard Evans and Bridget Logterman deserved recognition. Helping Edwards represent La Jolla-based Stratagene in the deal were L.A. Latham partner Samuel Weiner, and associates Eric Stier, Brian Wolfe, Holly Bauer and Noel Brock, all from the San Diego office.

Jessie Seyfer

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.